The U.S. Food and Drug Administration (FDA) has approved ProHeart® 12 (moxidectin), the new, first-ever once-yearly injection to prevent heartworm disease (caused by Dirofilaria immitis) in dogs 12 months of age and older. Its unique formulation of moxidectin microspheres provides long-lasting protection against heartworm disease and treats dogs for larval and adult hookworms (Ancylostoma caninumand Uncinaria stenocephala) existing at the time of administration. ProHeart 12 will provide customers with an advanced prevention option that will help increase compliance among dog owners and veterinarians.
- 1 vial $407.40
- 5 vial pack $364.80
- 10 vial pack $331.50
- An 8 ml vial will treat 352 lbs or about (8) 44 lb pound dogs.
ProHeart 12 fits in with the recommendation to provide year-round heartworm disease prevention, which can help to eliminate gaps in protection for a full year. ProHeart 12 is yet another example of the Zoetis commitment to veterinarians, as it can only be administered by certified veterinarians or certified veterinary hospital staff. Zoetis will publicly announce the FDA approval to customers starting after the holiday, with plans to start shipping ProHeart 12 in early August.
